🔬 Advancing RNA Nanotechnology at FNANO 2025
We’re proud to share that Dr. Thom LaBean, CSO and co-founder of Helixomer, presented at FNANO 2025, a premier conference for nucleic acid nanotechnology.
Dr. LaBean highlighted our progress in RNA origami-based therapeutics, showcasing how our platform addresses longstanding limitations of aptamer technologies—including instability, short half-life, and immune response. By combining rational design with clinical focus, Helixomer is building a new class of programmable therapeutics for precision medicine.
Thank you to the FNANO community for the opportunity to share our work and engage with leaders shaping the future of RNA nanotech.
🔗 Learn more at helixomer.com
📍 Event info: fnano.org
hashtag#FNANO2025 hashtag#Helixomer hashtag#RNAOrigami hashtag#BiotechInnovation hashtag#Aptamers hashtag#RNAtherapeutics hashtag#PrecisionMedicine hashtag#NucleicAcidNanotech hashtag#DrugDevelopment